Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Felip Font, E. [1 ]
Gettinger, S. N. [2 ]
Burgio, M. A. [3 ]
Antonia, S. J. [4 ]
Holgado, E. [5 ]
Spigel, D. R. [6 ]
Arrieta, O. [7 ]
Domine Gomez, M. [8 ]
Aren Frontera, O. [9 ]
Brahmer, J. [10 ]
Chow, L. Q. [11 ]
Crino, L. [12 ]
Butts, C. [13 ]
Coudert, B. [14 ]
Horn, L. [15 ]
Steins, M. [16 ]
Geese, W. J. [17 ]
Li, A. [17 ]
Healey, D. [17 ]
Vokes, E. E. [18 ]
机构：
[1] Hosp Univ Vall dHebron, Thorac Tumors Grp, Barcelona, Spain
[2] Yale Canc Ctr, Oncol, New Haven, CT 06510 USA
[3] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Oncol, Meldola, Italy
[4] H Lee Moffitt Canc Ctr & Res Inst, Oncol, Tampa, FL USA
[5] Hosp Madrid, Oncol, Norte Sanchinarro, Madrid, Spain
[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Med Oncol, Nashville, TN 37203 USA
[7] Inst Nacl Cancerol, Oncol, Mexico City, DF, Mexico
[8] Fdn Jimenez Diaz, Oncol, Madrid, Spain
[9] Ctr Int Estudios Clin, Oncol, Santiago, Chile
[10] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Oncol, Baltimore, MD 21231 USA
[11] Univ Washington, Oncol, Seattle, WA 98195 USA
[12] Osped Perugia, Oncol, Perugia, Italy
[13] Cross Canc Inst, Oncol, Edmonton, AB, Canada
[14] Ctr Georges Francois Leclerc, Oncol, Dijon, France
[15] Vanderbilt Ingram Canc Ctr, Thorac Oncol, Nashville, TN 37232 USA
[16] Heidelberg Univ Hosp, Thoraxklin, Oncol, Heidelberg, Germany
[17] Bristol Myers Squibb, Immunooncol, Princeton, NJ 08540 USA
[18] Univ Chicago Med & Biol Sci, Oncol, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1301PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Three-Year Follow-Up From checkMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
    Felip, Enriqueta
    Gettinger, Scott
    Burgio, Marco Angelo
    Antonia, Scott J.
    Holgado, Esther
    Spigel, David
    Arrieta, Oscar
    Domine, Manuel
    Aren Frontera, Osvaldo
    Brahmer, Julie
    Chow, Laura Q.
    Crino, Lucio
    Butts, Charles
    Coudert, Bruno
    Horn, Leora
    Steins, Martin
    Geese, William J.
    Li, Ang
    Healey, Diane
    Vokes, Everett E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 142 - 143
  • [2] Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
    Vokes, E. E.
    Ready, N.
    Felip, E.
    Horn, L.
    Burgio, M. A.
    Antonia, S. J.
    Frontera, O. Aren
    Gettinger, S.
    Holgado, E.
    Spigel, D.
    Waterhouse, D.
    Domine, M.
    Garassinoio, M.
    Chow, L. Q. M.
    Blumenschein, G., Jr.
    Barlesi, F.
    Coudert, B.
    Gainor, J.
    Arrieta, O.
    Brahmer, J.
    Butts, C.
    Steins, M.
    Geese, W. J.
    Li, A.
    Healey, D.
    Crino, L.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 959 - 965
  • [3] Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
    Chang, Jianhua
    Wu, Yi-Long
    Lu, Shun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Feng, Jifeng
    Wu, Lin
    Tu, Hai-Yan
    Zhang, Yiping
    Luft, Alexander
    Zhou, Jian-ying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Poddubskaya, Elena
    Soo, Ross A.
    Chia, Yee Hong
    Penrod, John R.
    Taylor, Fiona
    Lawrance, Rachael
    Blum, Steven, I
    Sun, Xiaowu
    Juarez-Garcia, Ariadna
    Moreno-Koehler, Alejandro
    Li, Ang
    Li, Amy
    Cheng, Ying
    LUNG CANCER, 2022, 165 : 71 - 81
  • [4] Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
    Borghaei, Hossein
    Gettinger, Scott
    Vokes, Everett E.
    Chow, Laura Q. M.
    Burgio, Marco Angelo
    Carpeno, Javier de Castro
    Pluzanski, Adam
    Arrieta, Oscar
    Frontera, Osvaldo Aren
    Chiari, Rita
    Butts, Charles
    Wojcik-Tomaszewska, Joanna
    Coudert, Bruno
    Garassino, Marina Chiara
    Ready, Neal
    Felip, Enriqueta
    Garcia, Miriam Alonso
    Waterhouse, David
    Domine, Manuel
    Barlesi, Fabrice
    Antonia, Scott
    Wohlleber, Markus
    Gerber, David E.
    Czyzewicz, Grzegorz
    Spigel, David R.
    Crino, Lucio
    Eberhardt, Wilfried Enst Erich
    Li, Ang
    Marimuthu, Sathiya
    Brahmer, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) : 723 - +
  • [5] Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
    Horn, Leora
    Spigel, David R.
    Vokes, Everett E.
    Holgado, Esther
    Ready, Neal
    Steins, Martin
    Poddubskaya, Elena
    Borghaei, Hossein
    Felip, Enriqueta
    Paz-Ares, Luis
    Pluzanski, Adam
    Reckamp, Karen L.
    Burgio, Marco A.
    Kohlhaeeufl, Martin
    Waterhouse, David
    Barlesi, Fabrice
    Antonia, Scott
    Arrieta, Oscar
    Fayette, Jerome
    Crino, Lucio
    Rizvi, Naiyer
    Reck, Martin
    Hellmann, Matthew D.
    Geese, William J.
    Li, Ang
    Blackwood-Chirchir, Anne
    Healey, Diane
    Brahmer, Julie
    Eberhardt, Wilfried E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (35) : 3924 - +
  • [6] Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
    Reck, M.
    Coon, C.
    Taylor, F.
    DeRosa, M.
    Penrod, J. R.
    Dastani, H.
    Orsini, L.
    Gralla, R. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S599 - S600
  • [7] Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
    Reck, M.
    Coon, C.
    Taylor, F.
    Derosa, M.
    Penrod, J. R.
    Dastani, H.
    Orsini, L.
    Gralla, R. J.
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [8] Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
    Crino, L.
    Horn, L.
    Felip, E.
    Frontera, O. Aren
    Burgio, M.
    Waterhouse, D.
    Blumenschein, G.
    Barlesi, F.
    Garassino, M.
    Holgado, E.
    Antonia, S.
    Spigel, D.
    Gainor, J.
    Gettinger, S.
    Geese, W.
    Li, A.
    Healey, D.
    Ready, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2302
  • [9] Advanced non-small Cell Lung Carcinoma (NSCLC) CheckMate-017 and-057 in the Update: Survival Advantage with Nivolumab vs. Docetaxel is still confirmed
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (12) : 834 - 835
  • [10] Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
    Lind, M.
    Gettinger, S.
    Borghaei, H.
    Brahmer, J.
    Chow, L.
    Burgio, M.
    De Castro Carpeno, J.
    Pluzanski, A.
    Arrieta, O.
    Aren Frontera, O.
    Chiari, R.
    Butts, C.
    Wojcik-Tomaszewska, J.
    Coudert, B.
    Garassino, M.
    Ready, N.
    Felip, E.
    Alonso Garcia, M.
    Waterhouse, D.
    Domine, M.
    Barlesi, F.
    Antonia, S.
    Wohlleber, M.
    Gerber, D.
    Czyzewicz, G.
    Spigel, D.
    Crino, L.
    Eberhardt, W.
    Li, A.
    Marimuthu, S.
    Vokes, E.
    LUNG CANCER, 2020, 139 : S49 - S50
12345